The EIF2AK4 Knockout 786-O Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population in which the EIF2AK4 gene, encoding the GCN2 (general control nonderepressible 2) kinase, has been disrupted to eliminate its expression in the 786-O human renal cell adenocarcinoma line. This genetically engineered model provides a powerful tool for dissecting the role of GCN2-mediated amino acid sensing and integrated stress response (ISR) signaling in a clear cell renal cell carcinoma (ccRCC) context. The polyclonal nature of the knockout pool enables immediate functional studies without the need for single-cell-clone isolation, making it suitable for high-throughput screening and population-level analyses of stress adaptation pathways.
The parental 786-O cell line is a well-characterized model of ccRCC, harboring a homozygous mutation in the von Hippel?CLindau (VHL) tumor suppressor gene that leads to constitutive stabilization of hypoxia-inducible factors (HIFs). This genetic background mimics the aberrant metabolic and angiogenic programs observed in the majority of sporadic ccRCC tumors, thereby offering a clinically relevant platform for investigating tumor cell responses to nutrient deprivation and therapeutic stress. The combination of VHL loss with targeted EIF2AK4 disruption allows researchers to examine how amino acid stress signaling intersects with HIF-driven oncogenic pathways.
GCN2 functions as a serine/threonine kinase that is activated by uncharged tRNAs accumulating during amino acid deprivation, ribosome stalling, or UV radiation. Upon activation, GCN2 directly phosphorylates the ?? subunit of eukaryotic initiation factor 2 (eIF2??) at Ser51, a key event in the ISR. Phosphorylated eIF2?? attenuates global cap-dependent translation while selectively promoting the translation of ATF4, a master transcription factor that induces stress-responsive genes such as DDIT3/CHOP and PPP1R15A/GADD34. GCN2 activation relies on its interaction with the ribosomal P-stalk and the GCN1?CGCN20 complex, positioning it as a direct sensor of translational stress at the ribosome. In this knockout model, the absence of GCN2 abrogates eIF2?? phosphorylation and downstream ATF4-dependent transcriptional reprogramming, thereby crippling cellular adaptation to amino acid limitation.
In the 786-O ccRCC background, loss of GCN2 function is expected to sensitize cells to nutrient stress and may alter metabolic dependencies, given the high reliance of renal carcinoma cells on amino acid uptake and mTOR signaling. The model is particularly relevant for exploring how cancer cells exploit the ISR to survive in the austere tumor microenvironment, and for identifying synthetic lethal interactions that could be exploited therapeutically. Moreover, it provides a clean background to study compensatory pathways that emerge upon chronic impairment of amino acid sensing, such as altered mTORC1 activity or alternative stress kinase activation.
Key experimental applications include investigating the ISR under controlled amino acid deprivation, evaluating GCN2-dependent transcriptional changes via RT-qPCR for EIF2AK4 and ATF4 target genes, and assessing cell viability under nutrient stress using standard proliferation or apoptosis assays. Western blotting for GCN2 and phospho-eIF2?? serves as a direct readout of knockout efficiency and pathway engagement. This model also facilitates drug-screening efforts aimed at modulators of GCN2 signaling or at compounds that exploit ISR deficiency in tumor cells. For further technical details or custom requests, please contact Ascent Research.
